Literature DB >> 10656442

The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients.

S Hansen1, D A Grabau, F B Sørensen, M Bak, W Vach, C Rose.   

Abstract

This study addresses the prognostic value of estimating angiogenesis by Chalkley counting in breast cancer. A population-based group consisting of 836 patients with operated primary, unilateral invasive breast carcinomas was included from a predefined region and period of time. The median follow-up time was 11 years and 4 months. The microvessels were immunohistochemically stained by antibodies against CD34. The Chalkley count was obtained by a 25-point grid within three, subjectively selected, vascular tumor areas of highest microvessel density. The Chalkley count was analyzed in three categories using predefined Chalkley cutoff points at five and seven. There were significant correlations between high Chalkley counts and axillary lymph node metastasis, large tumor size, high histological malignancy grade, and histological type. A high Chalkley count showed lower probabilities of recurrence-free survival (P < 0.0001) and overall survival (P < 0.0001). In the Cox multivariate analysis, the hazard ratio (and 95% confidence interval) showed that the increased risk to die were: 1.55 (1.19-2.03) with Chalkley counts between 5 and 7; 2.26 (1.72-2.98) with counts > or =7 compared with counts < or =5; and 1.46 (1.14-1.87) with counts > or =7 compared with counts between 5-7. The study confirmed that estimation of angiogenesis by Chalkley counting had independent prognostic value in breast cancer patients. The Chalkley count could be useful to stratify node-negative patients for adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656442

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Authors:  Lori Rice; Christine Pampo; Sharon Lepler; Amyn M Rojiani; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2010-10-23       Impact factor: 3.514

2.  Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.

Authors:  Danielle J McCullough; Linda M-D Nguyen; Dietmar W Siemann; Bradley J Behnke
Journal:  J Appl Physiol (1985)       Date:  2013-10-31

3.  RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Authors:  José Baselga; Claudio Zamagni; Patricia Gómez; Begoña Bermejo; Shigenori E Nagai; Bohuslav Melichar; Arlene Chan; Lászlo Mángel; Jonas Bergh; Frederico Costa; Henry L Gómez; William J Gradishar; Clifford A Hudis; Bernardo L Rapoport; Henri Roché; Patricia Maeda; Liping Huang; Gerold Meinhardt; Joshua Zhang; Lee S Schwartzberg
Journal:  Clin Breast Cancer       Date:  2017-05-22       Impact factor: 3.225

4.  Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.

Authors:  Benjamin D L Li; Jeffrey S Gruner; Fleurette Abreo; Lester W Johnson; Herbert Yu; Soheir Nawas; John C McDonald; Arrigo DeBenedetti
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

Review 5.  Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.

Authors:  Olivier Trédan; Magali Lacroix-Triki; Séverine Guiu; Marie-Ange Mouret-Reynier; Jérôme Barrière; François-Clément Bidard; Antoine-Laurent Braccini; Olivier Mir; Christian Villanueva; Philippe Barthélémy
Journal:  Target Oncol       Date:  2014-09-05       Impact factor: 4.493

6.  Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.

Authors:  Jehana James; Daryl J Murry; Anthony M Treston; Anna Maria Storniolo; George W Sledge; Carolyn Sidor; Kathy D Miller
Journal:  Invest New Drugs       Date:  2006-09-13       Impact factor: 3.850

7.  Quantitative estimates of vascularity in solid tumors by non-invasive near-infrared spectroscopy.

Authors:  M Kragh; B Quistorff; E L Lund; P E Kristjansen
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

8.  VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Authors:  X Bich Trinh; P A van Dam; P B Vermeulen; S J Van Laere; G G Van den Eynden; W A A Tjalma; L Y Dirix
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

9.  Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.

Authors:  Gurpreet S Kapoor; Timothy A Gocke; Sanjeev Chawla; Robert G Whitmore; Ali Nabavizadeh; Jaroslaw Krejza; Joanna Lopinto; Justin Plaum; Eileen Maloney-Wilensky; Harish Poptani; Elias R Melhem; Kevin D Judy; Donald M O'Rourke
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 10.  Intra-tumoural microvessel density in human solid tumours.

Authors:  J Hasan; R Byers; G C Jayson
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.